Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

A Double-Blind, Multicenter, Placebo-and Active-Controlled Acute and Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00035295

Enrollment

584

Registered

2002-05-03

Start date

2001-11-08

Completion date

2003-12-05

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

A clinical study to determine the efficacy and safety of an Treatment of MK0869 in the treatment of depression.

Detailed description

The duration of treatment is 8 weeks.

Interventions

DRUGMK0869, aprepitant

DRUGComparator: placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with Major Depressive Disorder

Design outcomes

Primary

Measure	Time frame
HAMD-17 total score at week 8. Tolerability.	—

Secondary

Measure	Time frame
CGI-I score at week 8, at least 50% reduction in the HAMD-17 total score, and Sheehan Disability Score at Week 8	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026